Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Lymphoma × elotuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Lymphoid 1

Conditions

Multiple Myeloma 13 Smoldering Multiple Myeloma 2 Recurrence 1 Lymphoma 1 Leukemia, Plasma Cell 1

Interventions

Rituximab 150 Cyclophosphamide 137 Vincristine 61 Etoposide 61 fludarabine phosphate 60 Doxorubicin 58 Prednisone 56 Filgrastim 50 Cytarabine 46 fludarabine 44 Methotrexate 44 Melphalan 44 Busulfan 42 Whole-Body Irradiation 38 Tacrolimus 33 Mycophenolic Acid 33 Granulocyte Colony-Stimulating Factor 31 Radiotherapy 27 Antilymphocyte Serum 27 Peripheral Blood Stem Cell Transplantation 25 Dexamethasone 24 Carmustine 22 Stem Cell Transplantation 20 Lenalidomide 19 Bortezomib 19 Cyclosporine 18 Gemcitabine 17 thymoglobulin 16 Calcium Dobesilate 16 Alemtuzumab 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01239797 2022-06-01

ELOQUENT - 2

Bristol-Myers Squibb

Phase 3 Completed

646 enrolled 16 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡